INmune Bio Inc — Cash Flow (NASDAQ:INMB)

Financials

Cash from operating activities -8.94 M-28.5 M-22.69 M-11.98 M-33.36 M-22.58 M -22.58 M Cash from investing activities —-15 M0——-1.04 M — Cash from financing activities 23.9 M96.36 M729 K-4.22 M18.21 M27.61 M 27.61 M Free cash flow -8.94 M-28.5 M-22.69 M-11.98 M-33.36 M-23.62 M -22.58 M

뉴스

INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript

루시드, INmune Bio 투자의견 상향…RDEB 치료제 주목

Lucid Capital Markets upgrades INmune Bio stock rating on RDEB therapy

INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript

아이엔뮤, RDEB 치료 데이터 관련 웨비나 개최

INmune Bio to host webinar on RDEB treatment data

알츠하이머, RDEB 치료제 개발에 박차

INmune Bio outlines 2025 progress on Alzheimer’s and RDEB therapies

INmune Bio, 알츠하이머 임상 데이터 발표 후 주가 하락

INmune Bio stock falls after new Alzheimer’s trial data

INmune Bio reports promising Alzheimer’s drug data at CTAD conference

인뮨 바이오, 경영진 고용 계약 체결 및 보상 내역 발표